Sigilon Therapeutics acquired by Eli Lilly (LLY) for $14.92/sh in cash plus contingent payments up to $111.64/sh
Last trade before it stopped trading $22.47 / Final CVR expires December 31, 2031.
Please read the SEC documents regarding this current security and understand that I own some of these shares. This isn’t an offer or solicitation to buy shares.
From 8k June 29th:
Contingent Value Right Agreement
At or prior to the Acceptance Time, Purchaser, Parent and the Rights Agent will enter into the CVR Agreement. Each holder of Shares, holders of Company Restricted Stock Units, holders of Company Stock Options (other than Company Stock Options that have an exercise price that equals or exceeds the Closing Amount) and holders of Company Warrants (other than Company Warrants that have an exercise price that equals or exceeds the Closing Amount) will become entitled to receive up to three cash payments, each such payment being contingent upon, and subject to, the achievement of the applicable milestones (the “Milestones”) prior to the earlier of the applicable Milestone Expiration (as defined in the CVR Agreement) and termination of the CVR Agreement. The CVRs are contractual rights only and not transferable except under certain limited circumstances, will not be certificated or evidenced by any instrument and will not be registered with the SEC or listed for trading. The CVRs will not have any voting or dividend rights and will not represent any equity or ownership interest in Parent, Purchaser or Company or any of their affiliates.
Each CVR represents a right to receive the following cash payments, without interest and less any applicable tax withholding (the “Milestone Payments”) if the following Milestones are achieved:
●First Dosing Milestone: $4.06 per CVR, payable upon the occurrence of the first human being patient being dosed with a product in a Phase I clinical trial prior to July 31, 2027;
●First Registration Purposes: Dosing Milestone $26.39 per CVR, payable upon the occurrence of the first patient being dosed with a product in a pivotal trial prior to the December 31, 2028; and
●Marketing Authorization Milestone: $81.19 per CVR, payable upon the occurrence of marketing authorization for a product in (a) the United States, (b) Japan or (c) three of France, the United Kingdom, Italy, Spain and German prior to December 31, 2031.
All expressions of opinion reflect the judgment of the author and are subject to change. The information should not be construed as a recommendation. The foregoing content is subject to change at any time without notice content provided herein is for informational purposes only there is no guarantee these statements or forecasts will prove correct. past performance is no guarantee of future results. Investing involves risk including the possible loss of capital.